ClinicalTrials.gg
Status unknownNCT04106596ICAREUpdated Sep 27, 2019

HLA Analysis in Autoimmune Encephalitis and Related Disorders

An observational study in Autoimmune Encephalitis, Imbic Encephalitis and Autoimmune Cerebellar Ataxia, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-27.

Primary conditionStiff-Person SyndromeRegistry: Autoimmune Diseases of the Nervous SystemReclassifiedWhy we changed it
Registry
Autoimmune Diseases of the Nervous System — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stiff-Person Syndrome
Why
  1. The study's listed conditions name Stiff-Person Syndrome, a narrower term within Autoimmune Diseases of the Nervous System.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospices Civils de Lyon · Observational

How we know

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Study summary

Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent limbic involvement, typical magnetic resonance imaging. Several autoantibodies (Ab) may be detected in AE, although its detection is not mandatory to establish a diagnosis. These Ab mainly recognize different synaptic and cell-surface proteins in the central nervous system, and are thought to be pathogenic as they alter the normal location or function of its antigens.

The primary trigger of the immune response is unknown for most of AE. In addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of AE. Human leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune diseases, due to its genetic complexity and key role in the adaptive immune response. The aim of the study is to describe HLA profile in three groups of autoimmune encephalitis and related disorders: anti-LGI1, anti-CASPR2 and anti-GAD neurological diseases.

02

Conditions studied

  • Autoimmune Encephalitis
  • Imbic Encephalitis
  • Autoimmune Cerebellar Ataxia
  • Stiff-person Syndrome

Browse trials for

03

In context

Stiff-Person Syndrome Reclassified

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Compared within Stiff-Person Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases of the Nervous System. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with autoimmune encephalitis or related disorders whose samples were sent for analysis at Centre de Référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, for anti-neural antibody study and then stored at the biobank Neurobiotec

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of anti-LGI1, anti-CASPR2 or anti-GAD antibodies in serum or cerebrospinal fluid;
  2. Clinical picture compatible with the detected antibody (limbic encephalitis in anti-LGI1; limbic encephalitis, neuromyotonia or Morvan's syndrome in anti-CASPR2; limbic encephalitis, cerebellar ataxia or stiff-person syndrome in anti-GAD

Exclusion criteria

Exclusion Criteria:

  • Absence of complete clinicobiological data.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with antibodies against LGI1

    This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.

  • Patients with antibodies against CASPR2

    This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.

  • Patients with antibodies against GAD

    This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.

06

What researchers measure

Primary outcomes

  1. HLA in autoimmune encephalitis and related disorders

    Description of HLA alleles and haplotypes carrier frequencies in autoimmune encephalitis and related disorders

    Time frame: 12 Months

  2. Clinical relevance of HLA in autoimmune encephalitis and related disorders

    Description of clinical differences among patients regarding their HLA status

    Time frame: 12 Months

07

Study locations

1 site
  • Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
    Lyon, France
    • Jerome HONNORAT, PhD · Contact4 72 35 78 08
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2019; primary completion for Feb 2020, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 27, 2019
StartEst.
Oct 1, 2019
Primary completionEst.
Feb 1, 2020
CompletionEst.
Oct 1, 2020
Last update
Sep 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04106596
Responsible party
Sponsor
First posted
Sep 27, 2019
Start date
Oct 1, 2019 (estimated)
Primary completion
Feb 1, 2020 (estimated)
Completion
Oct 1, 2020 (estimated)
Last update
Sep 27, 2019

Study contacts

Jerome HONNORAT, PhD
Contact
jerome.honnorat@chu-lyon.fr
4 72 35 78 08 ext. 33
Géraldine PICARD
Contact
geraldine.picard@chu-lyon.fr
4 72 35 58 42 ext. 33
Jerome HONNORAT, PhD
principal investigator · Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion